Stockscreener 앱 받기
95.05
1.57%
1.47
시장 영업 전:
103.12
8.07
+8.49%
전일 마감가:
$93.58
열려 있는:
$93.9
하루 거래량:
8.61M
Relative Volume:
1.08
시가총액:
$139.37B
수익:
$16.75B
순이익/손실:
$1.85B
주가수익비율:
76.04
EPS:
1.25
순현금흐름:
$2.37B
1주 성능:
+0.87%
1개월 성능:
-5.60%
6개월 성능:
+8.00%
1년 성능:
+39.74%
1일 변동 폭
$93.35
$95.61
1주일 범위
$92.70
$96.69
52주 변동 폭
$67.80
$107.17
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
Boston Scientific announces results for first quarter 2025 - Financial Times
Boston Scientific earnings missed by $0.29, revenue fell short of estimates - Investing.com
Boston Scientific’s SVP Brown Vance sells shares for $458,904 - Investing.com
Boston Scientific’s SVP Brown Vance sells shares for $458,904 By Investing.com - Investing.com India
Boston Scientific (BSX) Q1 Earnings Preview: Consistent Outperformance Expected - GuruFocus
Boston Scientific Presses Its Advantage in Pulsed Field Ablation - Morningstar
Earnings Preview: Boston Scientific - Benzinga
What To Expect From Boston Scientific’s (BSX) Q1 Earnings - Barchart.com
TD Cowen maintains Boston Scientific stock with $115 target - Investing.com
Bearish Options Trading Surges for Boston Scientific (BSX) | BSX Stock News - GuruFocus
Those who invested in Boston Scientific (NYSE:BSX) five years ago are up 157% - Yahoo Finance
Boston Scientific’s Strong Growth Prospects and Resilience Drive Buy Rating - TipRanks
Is Boston Scientific Corporation (BSX) the Best Low Volatility Stock to Buy Now? - Insider Monkey
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific gets analyst upgrade on Farapulse PFA strength - MassDevice
Should You Buy Boston Scientific Stock Ahead Of Q1 Earnings? - Barchart.com
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings? - Yahoo Finance
Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight - GlobeNewswire Inc.
Boston Scientific Corporation (BSX): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Boston Scientific (NYSE:BSX) Ticks All The Boxes When It Comes To Earnings Growth - Yahoo Finance
Needham Upgrades Boston Scientific (WBAG:BSXC) - Nasdaq
Needham upgrades Boston Scientific on easing competition, growth opportunities - Baystreet.ca
This Boston Scientific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
A Glimpse Into The Expert Outlook On Boston Scientific Through 13 Analysts - Benzinga
Needham raises Boston Scientific stock to Buy, target at $113 - Investing.com
Boston Scientific Corporation (BSX): A Bull Case Theory - Yahoo Finance
RBC Capital maintains Outperform on Boston Scientific, $116 target - Investing.com
Smart Pills Market Detailed In New Research Report 2025 | Boston - openPR.com
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX) - Yahoo Finance
Truist Lowers Price Target for Boston Scientific (BSX) Ahead of Q1 Results | BSX Stock News - GuruFocus
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Boston Scientific Corp. stock rises Friday, still underperforms market - MarketWatch
Boston Scientific price target lowered to $113 from $120 at Truist - TipRanks
Is Boston Scientific Gaining or Losing Market Support? - Benzinga
Boston Scientific (BSX) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave - BioWorld MedTech
Lobbying Update: $20,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed - Nasdaq
What to Expect From Boston Scientific’s Q1 2025 Earnings Report - Nasdaq
Boston Scientific (NYSE:BSX) Announces Robust Q4 Results With Increased Sales And Net Income - Yahoo Finance
Interventional Neurology Market Deep Research 2025-2032 | - openPR.com
What To Expect From Boston Scientific’s Q1 2025 Earnings Report - Barchart.com
PFA non-inferior, even superior, to cryoablation for paroxysmal AF - BioWorld MedTech
Boston Scientific Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution - Yahoo Finance
Health Rounds: Some early breast cancers may not need surgery after chemo - MarketScreener
Boston Scientific (BSX) Stock Moves -1.55%: What You Should Know - Yahoo Finance
Tariffs on medical devices could raise healthcare costs - The Business Journals
Boston Scientific Sued Over Endoscopic Medical Device Patent - Bloomberg Law News
Boston Scientific (BSX) Faces Pressure from New Tariffs - GuruFocus
Stryker, Boston Scientific down as new tariffs impact medtech industry - Seeking Alpha
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):